மோள் மேட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மோள் மேட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மோள் மேட் Today - Breaking & Trending Today

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

(2)
Regulatory News:
Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC) met one of the primary endpoints, demonstrating significant improvement in progression-free survival (PFS) at the planned primary analysis. A prespecified interim analysis for the second primary endpoint of overall survival (OS), conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab, but did not reach statistical significance. Based on the preliminary OS data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low. The trial will continue as planned to the final analysis of OS; results are anticipated in early 20 ....

France General , United States , Hong Kong , United Kingdom , New Zealand , South Korea , United Arab Emirates , Dominican Republic , Saudi Arabia , Russian Federation , Susan Hubbard , Michaelm Morrissey , Lindsay Treadway , Gemma Roper , Ipsen Euronext , Daiichi Sankyo Company , Drug Administration , Takeda Pharmaceutical Company , Exchange Commission , Exelixis Inc , International Agency For Research On Cancer , Public Affairs , European Union , Roche Group , Regulatory News , Exelixi President ,

Santhera Pharmaceuticals Holding AG: Santhera und ReveraGen geben neue 2,5-Jahres-Behandlungsdaten mit Vamorolone bei Duchenne-Muskeldystrophie bekannt

Santhera Pharmaceuticals Holding AG: Santhera und ReveraGen geben neue 2,5-Jahres-Behandlungsdaten mit Vamorolone bei Duchenne-Muskeldystrophie bekannt
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Eric Hoffman , Dario Eklund , Reveragen Biopharma , National Institute Of Health , Duchenne Research , Development Of Reveragens Leitsubstanz Vamorolone , Head External Communications , Foundation To Eradicate Duchenne , Us National Institute , Santhera Pharmaceuticals Holding , Santhera And , Vamorolone In Terms , Two Vbp , Patients Vamorolone Dosen , The Cooperative International , Baseline With , Cinrg Dmd Natural , The Practice , These Results , Studies Observed , Dmd Close , With An Adequate , Vamorolone Continues , Both Doses , Dmd Patienten Well ,

NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application

(2)
SHELTON, CT / ACCESSWIRE / March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the Company ), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection.
The Company is preparing a pre-IND application encompassing its two clinical drug candidates for the treatment of COVID-19 infected patients. Of these, NV-CoV-2 is the Company s broad-spectrum anti-coronavirus drug candidate based on its nanoviricides® platform that is expected to be capable of attacking most, if not all, SARS-CoV-2 variants and other coronaviruses. In addition, the Company is also developing NV-CoV-2-R that combines (1) the power of NV-CoV-2 to attack and potentially dismantle the virus particles outside cells, and (2) the power of remdesivir to block further production of virus particles inside cells. Blockin ....

United States , Dan Vergano , Anthony Fauci , Remdesivir Veklury , Exchange Commission , Committee For Medicinal Products Human , Nanoviricides Inc , Theracour Pharma Inc , European Medicines Agency , Drug Administration , Securities Exchange , Buzzfeed News , Better Surrogate Virus , Mol Med , Human Immunodeficiency Virus , Hepatitisb Virus , Hepatitisc Virus , Herpes Simplex Virus , Varicella Zoster Virus , Asian Bird Flu Virus , Japanese Encephalitis , West Nile Virus , Theracour Pharma , Securities Act , Securities Exchange Act , United States Securities ,

NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application

NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Remdesivir Veklury , Exchange Commission , Committee For Medicinal Products Human , Nanoviricides Inc , Theracour Pharma Inc , European Medicines Agency , Drug Administration , Securities Exchange , Better Surrogate Virus , Mol Med , Human Immunodeficiency Virus , Hepatitisb Virus , Hepatitisc Virus , Herpes Simplex Virus , Varicella Zoster Virus , Asian Bird Flu Virus , Japanese Encephalitis , West Nile Virus , Theracour Pharma , Securities Act , Securities Exchange Act , United States Securities , Good Manufacturing , Medicinal Products , Human Use ,

Amgen soumet une demande d'autorisation de mise sur le marché du sotorasib à l'Agence européenne des médicaments

Amgen soumet une demande d'autorisation de mise sur le marché du sotorasib à l'Agence européenne des médicaments
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Jessica Akopyan , Oaks Trish Rowland , Damgen Amgen , International Association For The Study Of Lung , European Medicines , Kras Mutation , Mutation Kras , World Conference , International Association , Kras The , Cpnpc With , D Amgen Oncology , D Amgen , Thousand Oaks Trish Rowland , Arvind Sood , Cancer Information , Cancer Europe , Mol Med , Mol Breast , Links Lead , ஒன்றுபட்டது மாநிலங்களில் , ஓக்ஸ் ட்ரிஷ் ரோலண்ட் , சர்வதேச சங்கம் க்கு தி படிப்பு ஆஃப் நுரையீரல் , ஐரோப்பிய மருந்துகள் , உலகம் மாநாடு ,